Get the Stockscreener App
25.34
0.13%
-0.0325
Xoma Corporation stock is traded at $25.34, with a volume of 540.
It is down -0.13% in the last 24 hours and up +0.88% over the past month.
XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
See More
Previous Close:
$25.37
Open:
$25.33
24h Volume:
540
Relative Volume:
0.14
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-0.01%
1M Performance:
+0.88%
6M Performance:
-1.03%
1Y Performance:
+0.27%
1-Day Range:
$25.33
$25.34
1-Week Range:
$25.30
$25.41
52-Week Range:
$23.32
$25.87
Xoma Corporation Stock (XOMAO) Company Profile
Name
Xoma Corporation
Sector
Industry
Phone
510 204 7200
Address
2200 Powell Street, Suite 310, EmeryVille
Compare XOMAO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XOMAO
Xoma Corporation
|
25.34 | 0 | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.82 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
520.29 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.94 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.53 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
267.12 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Xoma Corporation Stock (XOMAO) Latest News
XOMA Royalty Declares Quarterly Preferred Stock Dividends - GlobeNewswire
XOMA Preferred Stock Pays High-Yield Quarterly Dividend: 8.625% Series A, 8.375% Series B - Stock Titan
How the (XOMAO) price action is used to our Advantage - news.stocktradersdaily.com
Learn to Evaluate (XOMA) using the Charts - news.stocktradersdaily.com
Bank of America Corp DE Acquires 2,009 Shares of XOMA Co. (NASDAQ:XOMA) - Defense World
XOMA (NASDAQ:XOMA) Rating Increased to Buy at Wall Street Zen - Defense World
Trading (XOMAP) With Integrated Risk Controls - news.stocktradersdaily.com
XOMA Co. (NASDAQ:XOMA) Shares Sold by Squarepoint Ops LLC - Defense World
Nuveen Asset Management LLC Increases Stock Position in XOMA Co. (NASDAQ:XOMA) - Defense World
Long Term Trading Analysis for (XOMA) - news.stocktradersdaily.com
XOMA Co. (NASDAQ:XOMA) Shares Sold by BNP Paribas Financial Markets - Defense World
BioInvent secured up to 30 MUSD from XOMA royalty - Biostock
BioStock: BioInvent secured up to 30 MUSD from XOMA royalty - TradingView
Wall Street Zen Upgrades XOMA (NASDAQ:XOMA) to Buy - Defense World
XOMA Royalty purchases mezagitamab royalty rights from BioInvent International for $30M - MSN
HC Wainwright Issues Positive Outlook for XOMA Earnings - Defense World
(XOMAP) Trading Report - news.stocktradersdaily.com
XOMA Co. (NASDAQ:XOMAO) Short Interest Update - Defense World
XOMA stock holds Buy rating, $104 target from H.C. Wainwright By Investing.com - Investing.com Canada
XOMA stock holds Buy rating, $104 target from H.C. Wainwright - Investing.com Australia
XOMA Co. (NASDAQ:XOMAP) Short Interest Update - Defense World
XOMA’s (XOMA) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
XOMA Royalty Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
XOMA Stock: HC Wainwright & Co. Reiterates Buy Rating with $104 - GuruFocus
XOMA Purchases Future Mezagitamab Royalty Interests from BioInve - GuruFocus
Xoma Royalty Acquires Mezagitamab Royalty, Milestone Rights From BioInvent - marketscreener.com
XOMA Royalty (XOMA) Acquires Mezagitamab Interests from BioInvent - GuruFocus
XOMA Royalty (XOMA) Acquires Mezagitamab Interests from BioInven - GuruFocus
XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million - The Manila Times
XOMA Royalty Purchases Mezagitamab Royalty and Milestone - GlobeNewswire
(XOMAO) Technical Pivots with Risk Controls - news.stocktradersdaily.com
(XOMA) Trading Advice - news.stocktradersdaily.com
Northern Trust Corp Has $2.40 Million Holdings in XOMA Co. (NASDAQ:XOMA) - Defense World
XOMA (NASDAQ:XOMAO) Stock Price Up 0.1% – Still a Buy? - Defense World
XOMA (NASDAQ:XOMAP) Trading Up 1.5% – Still a Buy? - Defense World
Major Shareholder Sells Massive Chunk of Xoma Stock! - TipRanks
(XOMAP) Investment Report - news.stocktradersdaily.com
Leerink Partnrs Analysts Boost Earnings Estimates for XOMA - Defense World
FY2026 Earnings Estimate for XOMA Issued By Leerink Partnrs - Defense World
Results: XOMA Royalty Corporation Exceeded Expectations And The Consensus Has Updated Its Estimates - Yahoo Finance
(XOMA) Investment Analysis and Advice - news.stocktradersdaily.com
XOMA Royalty First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
XOMA Royalty Reports Strong Q1 2025 Results - TipRanks
XOMA Royalty Corp Q1 2025 Earnings: EPS of $0.24, Revenue Surges to $15.9 Million, Exceeding Estimates - GuruFocus
XOMA Royalty: Q1 Earnings Snapshot - New Haven Register
XOMA (XOMA) Surpasses Q1 Revenue Expectations with Strong Pipeli - GuruFocus
XOMA Royalty (XOMA) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance
XOMA earnings beat by $0.35, revenue topped estimates - Investing.com
XOMA Royalty Corporation Q1 2025 Financial Results - TradingView
XOMA Royalty Corp SEC 10-Q Report - TradingView
Xoma Corporation Stock (XOMAO) Financials Data
There is no financial data for Xoma Corporation (XOMAO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.06%
1.67%
Cap:
|
Volume (24h):